466.4

-0.73%↓

SANES

9.712

-0.69%↓

SAF

283

-1.57%↓

BBVA

18.825

+0.8%↑

BNP

83.28

+0.36%↑

466.4

-0.73%↓

SANES

9.712

-0.69%↓

SAF

283

-1.57%↓

BBVA

18.825

+0.8%↑

BNP

83.28

+0.36%↑

466.4

-0.73%↓

SANES

9.712

-0.69%↓

SAF

283

-1.57%↓

BBVA

18.825

+0.8%↑

BNP

83.28

+0.36%↑

466.4

-0.73%↓

SANES

9.712

-0.69%↓

SAF

283

-1.57%↓

BBVA

18.825

+0.8%↑

BNP

83.28

+0.36%↑

466.4

-0.73%↓

SANES

9.712

-0.69%↓

SAF

283

-1.57%↓

BBVA

18.825

+0.8%↑

BNP

83.28

+0.36%↑

Home・Akciju saraksts・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Slēgts

SektorsFinanšu

164.5 -2.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

163.7

Max

170.2

Galvenie mērījumi
By Trading Economics
Ienākumi	-17M 47M
Pārdošana	67M 772M
P/E Sektora vidējais	62.574 55.155
Dividenžu ienesīgums	0.42
Peļņas marža	6.125
Darbinieki	9,753
EBITDA	-19M 199M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+37.79% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.42% 4.95%
Nākamie ieņēmumi	2026. g. 23. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.7B 17B
Iepriekšējā atvēršanas cena	167.05
Iepriekšējā slēgšanas cena	164.5

Ziņu noskaņojums

By Acuity

50%

160 / 440 Rangs Finance

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

202.7 / 211.7 Atbalsts un pretestība

Sartorius Stedim Biotech. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. apr. 23:17 UTC

Peļņas

Samsung Forecasts Record First-Quarter Operating Profit

2026. g. 6. apr. 23:00 UTC

Karstas akcijas

Stocks to Watch: Health Insurers, Mawson, Owlet

2026. g. 6. apr. 22:13 UTC

Galvenie tirgus virzītāji

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026. g. 6. apr. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026. g. 6. apr. 17:09 UTC

Galvenie tirgus virzītāji

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026. g. 6. apr. 16:56 UTC

Galvenie ziņu notikumi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026. g. 6. apr. 14:47 UTC

Galvenie tirgus virzītāji

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026. g. 7. apr. 00:00 UTC

Galvenie ziņu notikumi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026. g. 6. apr. 23:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026. g. 6. apr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026. g. 6. apr. 23:36 UTC

Tirgus saruna

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026. g. 6. apr. 23:15 UTC

Tirgus saruna

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026. g. 6. apr. 22:14 UTC

Tirgus saruna

Correction to Live Cattle Futures Article

2026. g. 6. apr. 20:56 UTC

Tirgus saruna

Mexican Private Consumption Fell in January -- Market Talk

2026. g. 6. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 6. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026. g. 6. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026. g. 6. apr. 19:06 UTC

Tirgus saruna

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026. g. 6. apr. 18:36 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 17:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026. g. 6. apr. 17:13 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 16:33 UTC

Tirgus saruna

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026. g. 6. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. apr. 14:59 UTC

Peļņas

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Salīdzinājums

Cenas izmaiņa

Sartorius Stedim Biotech. Prognoze

Cenas mērķis

By TipRanks

37.79% augšup

Prognoze 12 mēnešiem

Vidējais 233 EUR 37.79%

Augstākais 262 EUR

Zemākais 210 EUR

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sartorius Stedim Biotech. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sartorius Stedim Biotech. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

202.7 / 211.7Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

160 / 440 Rangs Finanšu

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.